Sosei Group Co. (OTCMKTS:SOLTF – Get Free Report) saw a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,757,400 shares, a drop of 17.2% from the July 31st total of 2,121,800 shares. Based on an average daily volume of 300 shares, the short-interest ratio is presently 5,858.0 days.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on SOLTF shares. Citigroup lowered Sosei Group from a “buy” rating to a “sell” rating in a research note on Wednesday, June 28th. Jefferies Financial Group lowered Sosei Group from a “buy” rating to an “underperform” rating in a research note on Tuesday, June 27th.
Sosei Group Stock Down 0.3 %
Sosei Group Company Profile
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia.
- Five stocks we like better than Sosei Group
- How to Use the MarketBeat Stock Screener
- 2 Stocks to Get You Ready for the Holiday Season
- High Flyers: 3 Natural Gas Stocks for March 2022
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Sosei Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sosei Group and related companies with MarketBeat.com's FREE daily email newsletter.